cjc-1295 ipamorelin pulsatile growth hormone release + | GH Peptide Therapy CJC-1295/Ipamorelin Blend (No DAC) |

Follow-up bloodwork should occur at 8 to 12 weeks after starting therapy, then quarterly during ongoing use

First, to investigate expression differences, we will utilize RT-qPCR and Western blot (WB) techniques to analyze the expression levels of the EVI5, OGA, and TNFRSF14 genes and proteins in Jurkat, Raji, C6, OLN-93, and PC12 cells

Exclusion criteria: (1) pregnant and breastfeeding women (2) participants with a present or past history of hepatotoxic drug intake, alcoholism (3) self-reported evidence of viral hepatitis and (4) subjects who did not provide blood samples or complete the questionnaire

doi: 10.1016/j.ijbiomac.2025.140520 10